H
Henry R. Shinefield
Researcher at University of California, San Francisco
Publications - 139
Citations - 14261
Henry R. Shinefield is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Vaccination & Population. The author has an hindex of 53, co-authored 139 publications receiving 13944 citations. Previous affiliations of Henry R. Shinefield include Kaiser Permanente & Piedmont Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
Steven Black,Henry R. Shinefield,Bruce Fireman,Edwin Lewis,Paula Ray,John Hansen,Laura Elvin,Kathy M. Ensor,Jill G. Hackell,George R. Siber,Frank J. Malinoski,Dace V. Madore,Ih Chang,Robert Kohberger,Wendy J. Watson,Robert Austrian,Kathy Edwards +16 more
TL;DR: The Wyeth Lederle as discussed by the authors determined the efficacy, safety and immunogenicity of the CRM197 pneumococcal conjugate vaccine against invasive disease caused by vaccine serotypes and to determine the effectiveness of this vaccine against clinical episodes of otitis media.
Journal ArticleDOI
Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine
Timo Vesikari,David O. Matson,Penelope H. Dennehy,Pierre Van Damme,Mathuram Santosham,Zoe M. Rodriguez,Michael J. Dallas,Joseph F. Heyse,Michelle G. Goveia,Steven Black,Henry R. Shinefield,Celia D. C. Christie,Samuli Ylitalo,Robbin F. Itzler,Michele L. Coia,Matthew T. Onorato,Ben A. Adeyi,Gary S. Marshall,Leif Gothefors,Dirk Campens,Aino Karvonen,James P. Watt,Katherine L. O'Brien,Mark J. DiNubile,H Fred Clark,John W. Boslego,Paul A. Offit,Penny M. Heaton +27 more
TL;DR: This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts, and the risk of intussusception was similar in vaccine and placebo recipients.
Journal ArticleDOI
Influenza and the rates of hospitalization for respiratory disease among infants and young children.
Hector S. Izurieta,William W. Thompson,Piotr Kramarz,David K. Shay,Robert L. Davis,Frank DeStefano,Steven Black,Henry R. Shinefield,Keiji Fukuda +8 more
TL;DR: Infants and young children without chronic or serious medical conditions are at increased risk for hospitalization during influenza seasons, and routine influenza vaccination should be considered in these children.
Journal ArticleDOI
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.
Steven Black,Henry R. Shinefield,Stella Ling,John Hansen,Bruce Fireman,David Spring,Jack Noyes,Edwin Lewis,Paula Ray,Janelle Lee,Jill G. Hackell +10 more
TL;DR: The heptavalent CRM197 pneumococcal conjugate vaccine was given to infants at 2, 4, 6 and 12 to 15 months of age in a randomized, double blind trial and was effective in reducing the risk of pneumonia in young children.
Journal ArticleDOI
Impact of the pneumococcal conjugate vaccine on otitis media.
TL;DR: In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.